News and Trends 11 Aug 2022 Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout Synlogic, Inc. has announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks. The new candidate, SYNB2081, is a synthetic biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following the investigational new drug candidate SYNB1353 for the potential […] August 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Enrollment completed for trial looking at treatment of diabetic kidney disease Enrollment has been completed for a study of a regenerative cell therapy investigational product for intra-renal artery administration to treat diabetic kidney disease (DKD). U.S.-based Caladrius Biosciences Inc., a clinical-stage biopharma company that develops therapies designed to treat or reverse disease, made the announcement today (August 2). The phase 1b open-label, proof-of-concept study will look […] August 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis British Columbia-based Aurinia Pharmaceuticals Inc. announced today (July 22) that its voclosporin drug has been recommended for marketing authorization to treat adults with active lupus nephritis (LN). The Canadian biopharma company said it is committed to delivering therapeutics that change the course of autoimmune disease after the Committee for Medicinal Products for Human Use (CHMP) […] July 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 ZyVersa Therapeutics and Larkspur merge to become publicly traded biopharma company U.S. biopharma company ZyVersa Therapeutics, Inc., and Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, have entered into a definitive business combination agreement. The transaction is expected to provide ZyVersa with access to the public equity market, which the parties believe will escalate development of ZyVersa’s renal and inflammasome product candidate pipelines. Upon […] July 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 Spanish company, 3P Biopharmaceuticals, manufactures biomass to treat black fungus A biomass to treat a difficult and evasive fungal infection with a high mortality rate has been manufactured by Spanish organization, 3P Biopharmaceuticals (3P). It created BSG005 biomass for its partner and client, Biosergen, a Norwegian biotechnology company that has just announced a phase 2 clinical trial of the product against mucormycosis – also known […] July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2021 Farxiga’s Approval Fuels Chronic Kidney Disease Comeback Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […] June 8, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2020 Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M Update (31/03/2020): AM-Pharma has raised an extra €47M on top of an existing €116M equity round to fund an upcoming phase III trial of a treatment for acute kidney injury. The money will help the Dutch biotech to prepare for its upcoming phase III trial of a protein drug for acute kidney injury, which is […] March 31, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2020 Immune Marker in Blood May Predict Kidney Transplant Rejection Risk French researchers have found that the levels of certain immune cells in the blood of kidney transplant recipients may predict their future risk for transplant rejection. At present, kidney transplantation is the best treatment for people with end-stage renal disease but introducing a ‘foreign’ organ into someone’s body comes with the risk of rejection by […] March 13, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
Interview 18 Sep 2019 Why Communication is Key for Getting Ahead in Biotech Many biotech founders and executives look to VC investors for advice and inspiration, but the attraction can go both ways. After more than a decade of investing in life science companies, Renee Aguiar-Lucander, now CEO of Calliditas Therapeutics, decided it was time to try sitting on the other side of the table. Prior to moving […] September 18, 2019 - 11 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2019 €43M Series C to Launch UK Company’s Home Hemodialysis Kit Quanta Dialysis Technologies has raised €43.2M ($48M) to fund the commercial launch of a device that makes home hemodialysis more straightforward and economical for kidney failure patients. The UK-based Quanta will use the money to launch its technology in the UK later this year, and also apply for FDA approval. The technology previously obtained a […] July 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2019 Update: Hansa Biopharma Applies for EMA Market Approval for Kidney Transplant Drug Update (01/03/2019): Hansa Biopharma (previously named Hansa Medical) has filed an application for marketing authorization for imlifidase with the EMA also for use in patients undergoing kidney transplants. Update (18/10/2018): Imlifidase has just been given Fast Track Designation by the FDA for application in transplantation. The designation should accelerate the treatment through the FDA’s regulatory process, with […] March 1, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2019 Genetic Testing Improves Success of Kidney Transplants Genetic variations in cell surface proteins are able to predict kidney transplant success, shows Austrian research, serving as a potential screening tool for improving future transplants. Many kidney transplants fail over time because the patient’s immune system rejects the organ. This rejection happens because the immune system recognizes that particular proteins on the cell surface, such […] February 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email